Deep Dive: The GLP-1 Impact Background: Starting Tirzepatide (April 2024) In April 2024, I started Tirzepatide (Mounjaro/Zepbound) at 2.5mg, gradually escalating to 10mg over several months
Here at the BioDesign Wellness Center in Tampa, Fla., we offer Semaglutide as a treatment option for patients with insulin resistance, obesity, diabetes, or weight-loss resistance
Modulation of butyrate transport in caco-2 cells
The pooled prevalence of obesity is currently as high as 23.5%, and the general prevalence of diabetes among adults in the US is 6.3% (Sullivan et al., 2005)
GLUT1 knockdown markedly reduced glucose uptake and lactate production, and reduced the levels of decidualization markers (42) ( Figure 1 )
genetic test $298, LifeMD, or PlexusDxit helps to understand which biomarkers influence medication response and tolerability